Skip to content

periorbital rejuvenation& palpebral laxity with plasma jet

Efficacy and safety of plasma jet in periorbital rejuvenation & palpebral laxity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190407043192N1
Enrollment
70
Registered
2019-07-23
Start date
2018-12-11
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periorbital rejuvenation.

Interventions

Intervention group: patients fulfilling the study inclusion criteria will be provided with all the information concerning the procedure and informing the research properties of the treatment. Patients

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: People with chief complaint of palpebral laxity People with 35-65 years old

Exclusion criteria

Exclusion criteria: Unwillingness to participate to the study History of skin infections such as herpes simplex History of neuromuscular or connective tissue diseases Uncontrolled diabetes melitus Immunosuppressant drugs

Design outcomes

Primary

MeasureTime frame
Evaluation of periorbital rejuvenation : no response (75%). Timepoint: Before treatment ,one month after each treatment session , three months after the last treatment session. Method of measurement: Clinical images , Reviscometer device.

Secondary

MeasureTime frame
Evaluation of the patient satisfaction. Timepoint: Before treatment, one month after each treatment session ,three months after the last treatment session. Method of measurement: Based on the patient response to the question (unsatisfactory , partial satisfaction , totally satisfied).;Advers effects. Timepoint: Before treatment, one month after each treatment session ,three months after the last treatment session. Method of measurement: Based on the patient response to the question (infection , erythema , post inflammatory hyper or hypo pigmentation).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Beheshti

Shahid Beheshti University of Medical Sciences

ma_beheshti@yahoo.com+98 21 2274 1507

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026